Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
CYTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $1.79
Previous CloseN/A
Volume30.51K
Average Volume (3M)119.08K
Market Cap
$20.73M
Enterprise Value$33.94M
Total Cash (Recent Filing)$933.46K
Total Debt (Recent Filing)$48.49K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 14, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding28,614,000
10 Day Avg. Volume56,174
30 Day Avg. Volume119,082
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.13
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit34.71
Enterprise Value/Ebitda-1.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Cyclo Therapeutics News
PremiumCompany Announcements
Cyclo Therapeutics Merges with Rafael Holdings
PremiumPre-Earnings
Is CYTH a Buy, Before Earnings?
PremiumMarket News
3 Penny Stocks to Watch Now, 2/11/25
PremiumCompany Announcements
Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company announced it has completed enrollment for its 108-patient pivotal phase 3 trial of its lead drug candidate.
PatentsThe company received notice from the European Patent Office of a decision to grant a European patent application.
Bears Say
EarningsEPS was $(0.21), versus our and consensus estimate of $(0.17).
---
Ownership Overview
55.06% Insiders
2.57% Mutual Funds
4.47% Other Institutional Investors
35.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
CYTH FAQ
What was Cyclo Therapeutics’s price range in the past 12 months?
Cyclo Therapeutics lowest stock price was $0.55 and its highest was $1.79 in the past 12 months.
What is Cyclo Therapeutics’s market cap?
Cyclo Therapeutics’s market cap is $20.73M.
When is Cyclo Therapeutics’s upcoming earnings report date?
Cyclo Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 46 days.
How were Cyclo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cyclo Therapeutics overvalued?
According to Wall Street analysts Cyclo Therapeutics’s price is currently Overvalued.
Does Cyclo Therapeutics pay dividends?
Cyclo Therapeutics does not currently pay dividends.
What is Cyclo Therapeutics’s EPS estimate?
Cyclo Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Cyclo Therapeutics have?
Cyclo Therapeutics has 28,614,000 shares outstanding.
What happened to Cyclo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyclo Therapeutics?
Currently, no hedge funds are holding shares in CYTH
---
Cyclo Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-49.65%
12-Months-Change
Fundamentals
Return on Equity
184.06%
Trailing 12-Months
Asset Growth
-6.13%
Trailing 12-Months
Company Description
Cyclo Therapeutics
Cyclo Therapeutics, Inc. (CYTH) is a biotechnology company focused on developing treatments for rare and serious diseases. Specializing in the use of cyclodextrins, the company aims to advance its proprietary Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C (NPC), a rare genetic disorder. Cyclo Therapeutics operates within the pharmaceutical and healthcare sectors, leveraging its expertise in cyclodextrin technology to address complex medical needs.
---
CYTH Stock 12 Month Forecast
Average Price Target
―Technical Analysis
BioCryst
―
Arbutus Biopharma
―
Aurinia Pharmaceuticals
―
Axsome Therapeutics
―
Clearside Biomedical
―
Best Analysts Covering CYTH
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-27.85%
assigned a buy rating 7 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -27.85% per trade.
---